Multivariate logistic regression modeling was utilized to identify independent predictors of refusing RC.
INTRODUCTION AND OBJECTIVES: Despite the advantages of holmium laser (HoLEP) for concomitant treatment of prostate enucleation and lithiasis treatment (cystolitholapaxy) studies about the simultaneous use of these techniques in patients with BPH and concomitant bladder lithiasis are scarce. As a result of our enucleation program implemented in three centers in Madrid (Spain), a large series of BPH patients with large prostate volumes and high comorbidity burden, including patients with concomitant urolithiasis, was collected.
The objective of this study is to assess the influence of holmium laser cystolitholapaxy (HLC) concomitantly with holmium laser prostate enucleation (HoLEP) on patients with benign prostatic hyperplasia (BPH) presenting bladder calculi.
METHODS: Retrospective analysis of patients with BPH (with or without concomitant HLC) at three Spanish centers. Intraoperative variables (e.g., time and resected tissue), changes in functional parameters of the prostate, and frequency of complications (intraoperative, early postoperative, and at 12 months) in patients with and without HLC were compared.
RESULTS: The analysis included 963 patients aged 48 to 91 years, of which 54 (5.6%) underwent HLC to treat vesical lithiasis. Mean (range) prostate size (measured by transrectal ultrasound) was 79 (43-173) g and 91 (35-247) g for patients with and without concomitant HLC, respectively (p[0.080) All bladder calculi were successfully removed. No significant differences were found regarding enucleation and morcellation times, but total operation time was significantly higher in patients with HLC: mean (SD) of 78 (27) RESULTS: Seventy eight patients underwent HoLEP for glands >200cc3. Mean preoperative gland size was 255.9 cm3, and a mean of 157.2g was resected on final pathology. Mean enucleation time was 77 minutes, and mean morcellation time was 50.8 minutes. Patients stayed a mean of 1.8 days and had a catheter for a mean of 2.7 days. No patients were catheter dependent at last follow up. On subgroup analysis, comparing patients with preoperative gland size 200-299cc3 vs >300cc, there was no difference in mean operative time CONCLUSIONS: HoLEP provides a safe and efficient treatment option for patients who have massive gland BPH >200cm3. There was no difference in overall procedure time or enucleation time with increasing gland size, supporting previously published studies that HOLEP is a size independent intervention. There is an expected difference in morcellation time. This represents the largest series of
